{"id":"W3082639272","doi":"10.1016/j.ejca.2020.07.028","title":"Increased risk of immune checkpoint inhibitor–induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Medac; Les Laboratories Pierre Fabre; Novartis; Bristol-Myers Squibb; Novartis Pharma; Roche; Amgen","keywords":"Pembrolizumab; Medicine; Type 1 diabetes; Internal medicine; Melanoma; Diabetes mellitus; Adjuvant; Oncology; Gastroenterology; Cancer; Immunotherapy; Endocrinology; Cancer research","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004937595,0.0001678179,0.0004798558,0.00008086716,0.0000236039,0.000009593375,0.0001912198,0.00002330436,0.0001014074],"category_scores_gemma":[0.00008136059,0.00008994272,0.0001246405,0.0004222105,0.0001137863,0.00008239544,0.00002796813,0.0003415339,0.000001325357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000667602,"about_ca_system_score_gemma":0.0004239033,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001454008,"about_ca_topic_score_gemma":0.00002268344,"domain_scores_codex":[0.9983684,0.0002252471,0.0006596803,0.000132731,0.000442614,0.0001713403],"domain_scores_gemma":[0.9982186,0.00004213193,0.001043435,0.0002020674,0.0003654418,0.0001283557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1594145,0.0009469105,0.3922556,0.0004404215,0.003258665,0.00007994588,0.005778046,0.00009803532,0.3421692,0.000004820197,0.001891536,0.09366239],"study_design_scores_gemma":[0.02438767,0.01134209,0.8674718,0.001021021,0.0003217557,0.000004380945,0.000265979,0.00002667543,0.09042882,0.00000103958,0.0045672,0.0001615413],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899079,0.00807011,0.00001425132,0.001291326,0.00007921289,0.0002465297,0.000008614062,0.000005247341,0.0003768648],"genre_scores_gemma":[0.9986101,0.0005085638,0.000370553,0.0002587066,0.0001809069,0.000001000311,0.00000292508,0.0000399932,0.00002722176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4752162,"threshold_uncertainty_score":0.3667758,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0122356714177343,"score_gpt":0.2187317812198983,"score_spread":0.206496109802164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}